← Leaderboards
Jennifer Justice Kiser
University Of Colorado Denver
$3,749,896
Attributed
$3,749,896
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $542K · FY2005–19$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,749,896 · 5
By mechanism
R01$2,628,595 · 1
K23$829,291 · 1
R03$161,664 · 1
M01$130,346 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Robert Turner Schooley$73,100,957
- John G. Gerber$1,597,914
- Elizabeth Connick$17,363,459
- Thomas A Campbell$2,616,890
- Jose Ramon Castillo-Mancilla$3,529,866
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsBaseResponseDosePharmacologyRandomizedDrug KineticsHepaticPlasmaDrug InteractionsRegimenViral HepatitisHepatitis C VirusAdverse EffectsHepatitis CAntiviral AgentsPublic Health RelevanceIncidenceAnti-Retroviral AgentsInhibitor/AntagonistClinical TrialsIn VivoHemolytic AnemiaGenotype
Grant awards (14)
Antiviral pharmacology and adherence in drug users$521,567
R01 · FY2019 · DA · contact PI
Antiviral pharmacology and adherence in drug users$521,567
R01 · FY2018 · DA · contact PI
Antiviral pharmacology and adherence in drug users$521,567
R01 · FY2017 · DA · contact PI
Antiviral pharmacology and adherence in drug users$521,849
R01 · FY2016 · DA · contact PI
Antiviral pharmacology and adherence in drug users$542,045
R01 · FY2015 · DA · contact PI
Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC$167,815
K23 · FY2013 · DK · contact PI
Ribavirin depletes endogenous nucleotide pools$79,561
R03 · FY2013 · DK · contact PI
Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC$167,815
K23 · FY2012 · DK · contact PI
Ribavirin depletes endogenous nucleotide pools$82,103
R03 · FY2012 · DK · contact PI
Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC$167,837
K23 · FY2011 · DK · contact PI
Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC$164,522
K23 · FY2010 · DK · contact PI
Concentration-Controlled Ribavirin for the Treatment of Patients with Chronic HVC$161,302
K23 · FY2009 · DK · contact PI
PHARMACOLOGIC EVALUATION OF HIV-INFECTED PREGNANT WOMEN ON HAART$55,699
M01 · FY2007 · RR · contact PI
THE EFFECTS OF LOW-DOSE RITONAVIR ON THE RENAL CLEARANCE OF TENOFOVIR$74,647
M01 · FY2005 · RR